SOPHiA GENETICS Earnings Call Signals Strong Momentum

SOPHiA GENETICS (SOPH) reported Q3 revenue of $24.3M, up 25% YoY, with record analysis volumes and improved adjusted EBITDA loss of $6.1M. U.S. revenue grew 41%, and new customer wins were highlighted. Challenges include FX pressure and implementation delays.

Original reporting
Published Nov 15, 2026, 1:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 4:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SOPH
Bullish
medium confidence
Mentioned
$SOPH
Relevance
6/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$SOPHBullishMed
01

Why it matters

The earnings beat and loss narrowing provide a catalyst for short‑term price appreciation, while guidance on 2027 visibility supports a longer‑term bullish view.

02

Market read

First‑time disclosure of SOPH's Q3 financials and strategic wins offers a fresh data point for traders targeting AI‑driven health‑tech micro‑caps.

03

What to watch

FX pressure on euro/CHF revenues and front‑loaded bio‑pharma project costs may compress margins in the near term.

Relevance 6/10Novelty 8/10Timing: post‑earnings today

Background

SOPHiA Genetics (NASDAQ:SOPH) reported its Q3 2026 results, marking its strongest quarter to date with record analysis volumes and expanding U.S. customer base.

Company-level read

Ticker impact

$SOPHBullishMedium confidence
Context

Q3 earnings call disclosed 25% revenue growth to $24.3M, narrowed adjusted EBITDA loss and strong U.S. customer wins.

Expected impact

potential modest upside as investors price in higher revenue and narrowing losses

Evidence & confidence

Revenue beat and loss compression are new primary data; market typically reacts positively to such earnings improvements for micro‑caps.

Market effects

Strengthens the genomics/AI‑driven diagnostics sector, highlighting demand for liquid‑biopsy and bio‑pharma collaborations.

U.S. market exposure benefits from 41% revenue growth, while European and APAC regions show double‑digit expansion.

Adds to the broader narrative of AI‑enabled health‑tech growth, but impact is limited to niche investors.

Counterpoint

Execution backlog and ongoing legal costs could delay profitability, suggesting caution despite headline growth.

Key entities

  • AstraZeneca

    Collaborating on companion diagnostic programs mentioned in the earnings call.

  • Guardant Health

    Lost a patent injunction case, removing a potential liability for SOPH.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September